TWD 81.8
(-1.09%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 56.92 Million TWD | 10.69% |
2022 | 51.42 Million TWD | 25.45% |
2021 | 40.99 Million TWD | 48.14% |
2020 | 27.67 Million TWD | 229.33% |
2019 | -21.39 Million TWD | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q1 | 14.49 Million TWD | -11.81% |
2024 Q2 | 14.81 Million TWD | 2.21% |
2023 Q2 | 14.37 Million TWD | 0.0% |
2023 Q4 | 16.43 Million TWD | 0.0% |
2023 Q1 | 14.37 Million TWD | 118.63% |
2023 FY | 56.92 Million TWD | 10.69% |
2023 Q3 | 16.43 Million TWD | 14.33% |
2022 Q3 | 6.57 Million TWD | 0.0% |
2022 FY | 51.42 Million TWD | 25.45% |
2022 Q4 | 6.57 Million TWD | 0.0% |
2021 FY | 40.99 Million TWD | 48.14% |
2020 FY | 27.67 Million TWD | 229.33% |
2019 FY | -21.39 Million TWD | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
BIONET Corp. | 553.58 Million TWD | 89.717% |
DIVA Laboratories, Ltd. | 158.62 Million TWD | 64.112% |
Genetics Generation Advancement Corp. | 218.25 Million TWD | 73.918% |
Welgene Biotech Co.,Ltd. | 123.97 Million TWD | 54.083% |
TFBS Bioscience Inc. | 77.82 Million TWD | 26.858% |